CD4+ Extracellular Vesicles Activate CD8+ T Cells Against Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including surgical therapy, chemotherapy, and radiation therapy, are ineffective in eliminating metastasized cancer cells and often result in drug resistance, leading to high mortality rates and severe side effects, necessitating a more effective and less harmful approach.
Innovation Solution
A pharmaceutical composition containing CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles, which enhance the proliferation and cytotoxicity of CD8+ T cells to induce cancer cell death, offering a novel immune-based treatment strategy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (surgery, chemotherapy, radiation) are used, then cancer cells can be treated, but metastasized cancer cells remain and drug resistance develops
Solution Approach 1:
The patent uses extracellular vesicles as intermediary carriers to deliver cytotoxic substances and activate immune cells. These vesicles mediate the interaction between cancer cells and the immune system, enhancing the effectiveness of cancer treatment while reducing direct drug exposure that leads to resistance.
Solution Approach 2:
The patent leverages the body's own immune system (CD8+ T cells) to fight cancer. By activating these self-defense cells through extracellular vesicles, the treatment enables the body to autonomously identify and eliminate cancer cells, including metastasized ones, without relying on external drugs that can develop resistance.
2Reliability
If chemotherapy drugs are administered, then cancer cells are targeted, but serious side effects occur in normal tissues
Solution Approach 1:
The patent employs extracellular vesicles that can be selectively targeted to cancer cells through specific surface markers. This localizes the cytotoxic effect to cancer tissues only, spares normal tissues from drug exposure, and eliminates the widespread side effects associated with conventional chemotherapy while maintaining strong anticancer activity.
Solution Approach 2:
Extracellular vesicles serve as a targeted delivery intermediary that carries cytotoxic substances directly to cancer cells. This mediation system ensures that harmful substances are delivered precisely to the intended target (cancer cells) rather than being distributed systemically, thereby avoiding damage to normal tissues.
3Productivity
If anticancer drugs are administered repeatedly, then tumor shrinks initially, but therapeutic effects are lost due to resistance
Solution Approach 1:
The patent uses a dynamic activation system where extracellular vesicles continuously stimulate CD8+ T cells to maintain high levels of cytotoxic activity. This dynamic engagement prevents cancer cells from adapting or developing resistance, as the immune response is constantly renewed and intensified, ensuring long-term therapeutic effectiveness.
Solution Approach 2:
The patent establishes continuous activation of CD8+ T cells through repeated exposure to extracellular vesicles. This continuous stimulation maintains the immune system's attack on cancer cells over time, preventing the therapeutic effect from waning or being overcome by resistance mechanisms that occur with intermittent or single-dose chemotherapy.
Data Source
AI summary
The present invention relates to a composition, for prevention or treatment of cancer diseases, comprising CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as an active ingredient. It was found that the secretion of extracellular vesicles from cytokine-activated CD4+ T cells increases and the extracellular vesicles enhance proliferation and activity of CD8+ T cells to induce the death of cancer cells, thereby augmenting an anticancer effect. Thus, the present invention provides the CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as a pharmaceutical agent or an immunotherapeutic agent for cancer diseases, and a method for activating CD8+ T cells by using CD4+ T cell-derived extracellular vesicles to prepare CD8+ T cells showing excellent anticancer activity as described above.